Texas Tech University Health Science Center, Lubbock.
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine.
Curr Opin Gastroenterol. 2023 Nov 1;39(6):482-489. doi: 10.1097/MOG.0000000000000981. Epub 2023 Sep 5.
The recognition that Helicobacter pylori should be considered and treated as an infectious disease has yet to fundamentally change diagnostic and treatment practices and has resulted in many controversies.
We discuss the following controversies: whether the current 'per-patient' approach to H. pylori testing based on symptoms should be expanded to include achieving population-level H. pylori eradication, whether H. pylori should be approached as an infectious gastrointestinal disease similar to that of other infectious diseases of similar severity and outcome, whether treatment of H. pylori should be primarily empiric or based on antibiotic susceptibility and locally proven successful therapies as are other infectious diseases, whether it is necessary to obtain confirmation of treatment success in every patient treated for H. pylori , and whether potassium-competitive acid blockers should replace proton pump inhibitors in H. pylori therapy.
Available guidelines and meta-analyses do not yet address H. pylori as an infectious disease. The diagnosis and management and treatment success of H. pylori infections trails behind that of other important infectious diseases. We provide new insights and propose changes in the traditional understanding required to modernize the management of H. pylori infections.
尽管人们已经认识到幽门螺杆菌应被视为一种传染病并加以治疗,但这尚未从根本上改变诊断和治疗实践,并且由此产生了许多争议。
我们讨论了以下争议:目前基于症状的“个体化”幽门螺杆菌检测方法是否应扩大到包括实现人群层面的幽门螺杆菌根除,是否应将幽门螺杆菌视为一种类似其他严重程度和结局相似的传染性胃肠道疾病,是否应像其他具有相似严重程度和结局的传染性疾病一样,主要根据抗生素敏感性和当地已证明有效的治疗方法来治疗幽门螺杆菌,是否有必要在治疗的每位幽门螺杆菌患者中都确认治疗成功,以及钾竞争性酸阻滞剂是否应替代质子泵抑制剂用于幽门螺杆菌治疗。
现有的指南和荟萃分析并未将幽门螺杆菌视为一种传染病。幽门螺杆菌感染的诊断、管理和治疗成功率落后于其他重要的传染性疾病。我们提供了新的见解,并提出了改变传统观念的建议,以实现幽门螺杆菌感染管理的现代化。